Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Risdiplam (RO7034067) 是一种中枢和外周分布的 SMN2 前 mRNA 剪接修饰剂,可增加运动神经元存活 (SMN) 蛋白水平。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 497 | 现货 | ||
2 mg | ¥ 729 | 现货 | ||
5 mg | ¥ 1,220 | 现货 | ||
10 mg | ¥ 1,980 | 现货 | ||
25 mg | ¥ 3,710 | 现货 | ||
50 mg | ¥ 5,330 | 现货 | ||
100 mg | ¥ 7,520 | 现货 | ||
500 mg | ¥ 14,800 | 现货 |
产品描述 | Risdiplam (RO7034067) (RG7916) is orally administered. Risdiplam is a centrally and peripherally distributed SMN2 pre-mRNA splicing modifier which increases survival motor neuron (SMN) protein levels[1]. |
体外活性 |
Risdiplam is a modifier of SMN2 splicing, leading to an increase in SMN2 full-length transcript and thus functional SMN protein. Risdiplam modulates SMN2 pre-mRNA splicing towards the production of full-length SMN2 mRNA and increases SMN protein levels [1]. Spinal muscular atrophy (SMA) type I remains the most common genetic disease resulting in death in infancy. Characterized by progressive motor and respiratory muscle weakness, this autosomal recessive neuromuscular disorder is caused by low levels of the survival motor neuron protein (SMN) due to inactivating bi-allelic deletions and other disabling mutations in the survival motor neuron 1 (SMN1) gene[1]. Risdiplam is a modifier of SMN2 splicing, leading to an increase in SMN2 full-length transcript and thus functional SMN protein. Risdiplam modulates SMN2 pre-mRNA splicing towards the production of full-length SMN2 mRNA and increases SMN protein levels [1]. Spinal muscular atrophy (SMA) type I remains the most common genetic disease resulting in death in infancy. Characterized by progressive motor and respiratory muscle weakness, this autosomal recessive neuromuscular disorder is caused by low levels of the survival motor neuron protein (SMN) due to inactivating bi-allelic deletions and other disabling mutations in the survival motor neuron 1 (SMN1) gene[1]. |
别名 | RO7034067, RG7916 |
分子量 | 401.46 |
分子式 | C22H23N7O |
CAS No. | 1825352-65-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 1mg/ml (insoluble), Sonication is recommended.
Ethanol: 2 mg/mL (4.98 mM), Sonication is recommended.
H2O: 2.22 mg/mL (5.53 mM), when pH is adjusted to 6 with HCl. Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / H2O | 1 mM | 2.4909 mL | 12.4545 mL | 24.9091 mL | 62.2727 mL |
H2O | 5 mM | 0.4982 mL | 2.4909 mL | 4.9818 mL | 12.4545 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Risdiplam 1825352-65-5 Cell Cycle/Checkpoint DNA Damage/DNA Repair DNA/RNA Synthesis RG 7916 Inhibitor RO 7034067 RO7034067 RG-7916 RO-7034067 inhibit RG7916 inhibitor